135048-93-0

Upstream product

• 135048-94-1 4-(3-bromophenyl)tetrahydro-2H-pyran-4-ol 
• 74-88-4 methyl iodide 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 135048-92-9 4-methoxy-4-[3-(naphth-2-ylthio)phenyl] tetrahydropyran 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) C1, Br, I, -CN, -CH3, or -CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and pyrimidinyl; or (iv) a bicyclic heteroaryl selected from indolyl, pyrrolopyridinyl, pyrazolopyridinyl and benzo[d]oxazolyl; wherein each of said 5-membered, 6-membered, and bicyclic heteroaryl is substituted with zero to 1 Ra and zero to 1 Rb; and R1, R2, R3, R4, R5, R6, Ra, and Rb are defined herein. Also disclosed are methods of using such compounds as modulators of PI3K, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES

The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C1-10heteroaryl, C6-14aryl or C6- 10heterocycloalkylaryl; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C3-6 cycloalkyl, or C1-6heterocycloalkyl, each of which are optionally substituted; X represents -CR3R4-(CR5R6)n-(CR7=CR8)m-(C6-14aryl)r-(C1-10heteroaryl)s-(CR9R10)p- (CR11 = CR12)q, R2 represents C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C1-12alkylsilyl, C6-30alkylarylsilyl, C1-10heteroaryl, C6-14aryl, C1-10heterocycloalkyl, C1-10heterocycloalkenyl, C1-8cycloalkyl, C1-18cycloalkenyl, each of which is optionally substituted, or R2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

OXIME DERIVATIVES

The invention concerns oxime derivatives of the formula I wherein R4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di(1-4C)alkylamino and (1-4C)alkyl; RS includes hydrogen, (1-4C)alkyl, (3-4C)alkeny1,(3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4-C)alkyl and hydroxy-(2-4C)alky1;Arl is phenylene or a hetercaryl diradical; Al is a direct link to XI, or Al is (1-4C)alkylene; XI is oxy, thio, sulphinyl or sulphonyl; Ar2 is phenylene or a heteroaryl diradical; RI is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkyny1; and R2 and R3 together form a group of the formula -A2. X2-A3- which together with the carbon atom to which A2 and A3 are attached define a ring having 5 or 6 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable sah thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.

5-lipoxygenase inhibitors quinoxalinyl derivatives

The invention concerns a heterocyclic derivative of the formula I STR1 wherein Q is an optionally substituted quinoxalinyl or a hydrogenated derivative thereof X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R1 is (1-6C)alkyl, (3-6C)alkenyl or (3-6C)alkynyl; and R2 and R3 together form a group of the formula --A2 --X2 --A3 -- which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 4 to 7 ring atoms, wherein A2 and A3, which may be the same or different, each is (1-4C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

BICYCLIC HETEROCYCLIC DERIVATIVES AS 5-LIPOXYGENASE INHIBITORS

The invention concerns a bicyclic heterocyclic derivative of the formula I wherein Q is an optionally substituted 9-membered bicyclic heterocyclic moiety containing 1 or 2 N's and optionally a further N, O or S heteroatom; A1 is a direct link to X1 or (1-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or pyridylene; R1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R2 and R3 together form a group of the formula ?A2?X2?A3? which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl or sulphonyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase

ARYL DERIVATIVES

The invention concerns an aryl derivative of the formula I, wherein Ar1 is optionally substituted phenyl, naphthyl or a heterocyclic moiety, and X1 is oxy, thio, sulphinyl, sulphonyl, difluoromethylene, imino, (1-4C)alkylimino or optionally substituted (1-4C) alkylene, or X1 is a group of the formula wherein X4 is oxy, thio, sulphinyl, sulphonyl or carbonyl and each R is hydrogen, methyl or ethyl each of Ar2 and Ar3 is optionally substituted phenylene X2 is oxy, thio, sulphinyl or sulphonyl R1 is (1-4C)alkyl and R2 and R3 together form a group of the formula A1 X3 A2 which together with the carbon atom to which A1 and A2 are attached define a ring having 5 to 7 ring atoms, wherein each of A1 and A2 is (1-3C) alkylene and X3 is oxy, thio, sulphinyl or sulphonyl which compounds are inhibitors of 5-lipoxygenase and are useful in the treatment of inflammatory or allergic disease

5-LIPOXYGENASE INHIBITORS QUINOLINE OR ISOQUINOLINE DERIVATIVES

The invention concerns a heterocyclic derivative of the formula I wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R1 is (1-6C)alkyl, (3-6C)alkenyl or (3-6C)alkynyl; and R2 and R3 together form a group of the formula ?A2?X2?A3? which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 4 to 7 ring atoms, wherein A2 and A3, which may be the same or different, each is (1-4C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase

SULPHONAMIDE DERIVATIVES

The invention concerns sulphonamide derivatives of the formula I wherein R1 includes (1-4C)alkyl; R2 and R3 together form ?A2 ?X2 ?A3? which defines a ring having 5 to 7 ring atoms, wherein A2 and A3 each is (1-3 C)alkylene and X2 is oxy, thio, sulphinyl or sulphonyl; A1 is a direct link to X1 or is (1-3 C)alkylene; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or Ar is pyridylene; Q is nitrogen or of the formula CR7, wherein R7 includes hydrogen, halogeno, (1-4 C)alkyl and (1-4 C)alkoxy; each of R4 and R5 is (1-4 C)alkyl, (3-4 C)alkenyl, (3-4 C)alkynyl or optionally substituted phenyl, benzyl or pyridyl, or R5 may be hydrogen; and R6 has any of the meanings defined for R7; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors

BENZOXAZINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENES

The invention concerns a bicyclic heterocyclic compound of the formula I wherein Q is an optionally substituted 10-membered bicyclic heterocyclic moiety containing 1 or 2 N's and a further O or S heteroatom; A1 is a direct link to X1 or (1-3C)alkylene; X1 is oxy, thio, sulphinyl, sulphonyl or imino; Ar is optionally substituted phenylene or pyridylene; R1 is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; and R2 and R3 together form a group of the formula -A2-X2-A3- which, together with the carbon atom to which A2 and A3 are attached, defines a ring having 5 to 7 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl or sulphonyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase